These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 33188886)
1. Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. Goldsmith SR; Burkhoff D; Gustafsson F; Voors A; Zannad F; Kolkhof P; Staedtler G; Colorado P; Dinh W; Udelson JE J Card Fail; 2021 Feb; 27(2):233-241. PubMed ID: 33188886 [TBL] [Abstract][Full Text] [Related]
2. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Urbach J; Goldsmith SR Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837 [TBL] [Abstract][Full Text] [Related]
3. Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236 [TBL] [Abstract][Full Text] [Related]
4. Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure? Goldsmith SR; Udelson JE; Gheorghiade M J Card Fail; 2018 Feb; 24(2):112-114. PubMed ID: 29329950 [TBL] [Abstract][Full Text] [Related]
6. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022 [TBL] [Abstract][Full Text] [Related]
7. A new approach to treatment of acute heart failure. Goldsmith SR J Cardiol; 2016 May; 67(5):395-8. PubMed ID: 26946929 [TBL] [Abstract][Full Text] [Related]
8. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131 [TBL] [Abstract][Full Text] [Related]
9. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C; JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438 [TBL] [Abstract][Full Text] [Related]
10. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C; JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814 [TBL] [Abstract][Full Text] [Related]
11. Vasopressin receptor antagonists in heart failure. Hobbs RE; Tang WH Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127 [TBL] [Abstract][Full Text] [Related]
12. Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. Vaduganathan M; Mentz RJ; Greene SJ; Senni M; Sato N; Nodari S; Butler J; Gheorghiade M Expert Rev Cardiovasc Ther; 2015; 13(7):799-809. PubMed ID: 26106934 [TBL] [Abstract][Full Text] [Related]